Gilead Sciences, Inc. (GILD) Position Reduced by Charter Trust Co.

Charter Trust Co. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 12,069 shares of the biopharmaceutical company’s stock after selling 1,249 shares during the period. Charter Trust Co.’s holdings in Gilead Sciences were worth $854,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of GILD. Parnassus Investments CA boosted its stake in Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the period. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after purchasing an additional 2,727,063 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Gilead Sciences by 75.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock worth $173,148,000 after purchasing an additional 1,092,206 shares during the period. AQR Capital Management LLC boosted its stake in Gilead Sciences by 25.7% in the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock worth $354,070,000 after purchasing an additional 1,066,172 shares during the period. Finally, Swiss National Bank boosted its stake in Gilead Sciences by 26.9% in the 1st quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock worth $317,059,000 after purchasing an additional 989,400 shares during the period. 73.97% of the stock is owned by hedge funds and other institutional investors.

GILD has been the subject of a number of research reports. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Thursday, August 31st. Deutsche Bank AG reissued a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Credit Suisse Group reissued an “outperform” rating and set a $85.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 target price for the company in a research note on Monday, June 26th. Eleven analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $83.79.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://weekherald.com/2017/09/19/gilead-sciences-inc-gild-position-reduced-by-charter-trust-co.html.

Shares of Gilead Sciences, Inc. (GILD) traded down 0.8195% during mid-day trading on Tuesday, hitting $82.2901. 2,986,146 shares of the stock traded hands. The firm has a market capitalization of $107.46 billion, a P/E ratio of 8.9378 and a beta of 1.19. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company’s 50 day moving average is $77.36 and its 200 day moving average is $70.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.08 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.78 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is presently 22.58%.

In related news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders sold 466,819 shares of company stock worth $36,740,240 over the last three months. Insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply